Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Account Payables (2016 - 2020)

Harvard Bioscience (HBIO) has disclosed Change in Account Payables for 11 consecutive years, with -$154000.0 as the latest value for Q4 2020.

  • On a quarterly basis, Change in Account Payables fell 1500.0% to -$154000.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $511000.0, a 124.95% increase, with the full-year FY2020 number at $511000.0, up 124.95% from a year prior.
  • Change in Account Payables was -$154000.0 for Q4 2020 at Harvard Bioscience, up from -$585000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.0 million in Q4 2018 to a low of -$2.7 million in Q1 2016.
  • A 5-year average of -$163750.0 and a median of -$125000.0 in 2017 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 1641.67% in 2018; the steepest drop was 2598.8% in 2018.
  • Harvard Bioscience's Change in Account Payables stood at $372000.0 in 2016, then tumbled by 135.48% to -$132000.0 in 2017, then skyrocketed by 1641.67% to $2.0 million in 2018, then tumbled by 99.46% to $11000.0 in 2019, then plummeted by 1500.0% to -$154000.0 in 2020.
  • Per Business Quant, the three most recent readings for HBIO's Change in Account Payables are -$154000.0 (Q4 2020), -$585000.0 (Q3 2020), and -$72000.0 (Q2 2020).